




Contents lists available at ScienceDirect

Journal of Clinical Neuroscience

journal homepage: www.elsevier.com/locate/jocn

Short communication

DNA methylation of *DLG4* and *GJA-1* of human hippocampus and prefrontal cortex in major depression is unchanged in comparison to healthy individuals

Oliver Kaut^{a,1}, Amit Sharma^{a,1}, Ina Schmitt^a, René Hurlmann^b, Ullrich Wüllner^{a,c,*}^a Department of Neurology, University Clinic Bonn, Bonn, Germany^b Division of Medical Psychology, University of Bonn Medical Center, 53105 Bonn, Germany^c German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

ARTICLE INFO

Article history:

Received 15 February 2017

Accepted 21 May 2017

Available online xxxxx

Keywords:

Depression

DNA methylation

DLG4 (*PSD-95*)*Connexin43* (*GJA-1*)

ABSTRACT

Epigenetic alterations provide a potential mechanism to account for the numerous gene-environment interactions that have been reported in association with neuropsychiatric phenotypes. In context to major depression disorder (MDD), where postmortem and neuroimaging studies provide insights into dysfunctional brain regions, involvement of genetic heterogeneity also revealed the complexity of this disorder. Despite intensive research during the past several decades and information from genome wide studies, pathophysiology of depressive disorders remained elusive. To evaluate the impact of epigenetic pressure on this disease, we took advantage of DNA isolated from different sections of human brain (prefrontal cortex and hippocampus) from clinically well defined depressed patients and healthy individuals and performed pyrosequencing for DNA methylation analysis. Herein, we focused on two genes *DLG4* (*PSD-95*) and *GJA-1* (*Connexin43*) known to be associated with neuropsychiatric behavior. Comparing MDD with controls we found no differences of DNA methylation. Our results clearly demonstrate that DNA methylation levels on these particular genes are not associated with depression related phenotype.

© 2017 Elsevier Ltd. All rights reserved.

1. Introduction

Epigenetic regulations have been implicated in several human diseases, including neuropsychiatric disorders [1–3]. Studies from animal models have shown that early life stress can leave persistent epigenetic marks in the genome, which alter gene expression and can later on influence neural and behavioural function through adulthood [4–6]. Furthermore, administration of epigenetic inhibitor has also been shown to produce an antidepressant effect in an animal model system [7]. Involvement of epigenetics in human depression, which is a psychological condition that presents with wide-ranging symptoms along with neuronal structural changes in brain has been widely discussed [8–12]. In this particular study, we selected two independent genes (*DLG4* and *GJA-1*) which are known to be associated with neuropsychiatric behaviors. We determined their epigenetic status by pyrosequencing method by

using tissues samples isolated from different sections of brain regions (PFC: Prefrontal cortex, HIP: Hippocampus) from individuals with MDD vs. healthy controls.

2. Results and Discussion

First, we selected *DLG4* (*discs large homolog 4*) gene, which encodes a protein named PSD-95 (postsynaptic density protein 95) also known as *SAP-90* (*synapse-associated protein 90*) and has been previously implicated in studies related to depression [13–15]. Interestingly, levels of NMDA receptors and *PSD-95*, were found to be reduced in the postmortem samples of prefrontal cortex Brodmann's area 10 (BA10) in depressed patients as compared to psychiatrically healthy controls [16]. However, increased immunoreactivity levels of *NR2A* and *PSD-95* were reported in amygdala samples of depressed individuals [17]. Therefore, for this particular gene on chromosome 17, we selected six CpG sites embedded between CpG island 41 and neighboring *ACADVL* gene. To evaluate DNA methylation, we designed pyrosequencing analysis for two independent genomic locations within *DLG4* locus: CpG 1–3 (Chromosome17: 7215813–7215862 bp) and CpG 4–6 (Chromosome17: 7216811–7216860 bp) respectively (Fig. 1A). In the absence of a well-defined promotor region, our analysis on

* Corresponding author at: Department of Neurology, University Hospital Bonn, Sigmund-Freud-Straße 25, 53127 Bonn, Germany.

E-mail addresses: oliver.kaut@ukbonn.de (O. Kaut), amit.sharma@ukbonn.de (A. Sharma), ina.schmitt@ukbonn.de (I. Schmitt), rene.hurlmann@ukbonn.de (R. Hurlmann), ullrich.wuellner@ukbonn.de (U. Wüllner).

¹ These authors contributed equally to this work.




Fig. 1. DNA methylation analysis in depression phenotype. (A) Genomic structure of *DLG4* (*PSD-95*) showing six CpG sites (CpG1–3 and CpG4–6) selected to compare patients with major depressive disorder (MDD) and healthy controls. (B) Pyrosequencing results of *DLG4* gene [Prefrontal cortex (Left panel) and Hippocampus (right panel)] have been demonstrated. (C) DNA methylation levels measured at seven CpG sites of *GJA-1* locus has been shown for prefrontal cortex and hippocampus regions of the brain.

selected CpG sites clearly demonstrates that although methylation levels for CpG 1–3 are higher (10–15% methylation range) than CpG 4–6 (5–10% methylation range), no observable differences exist among patients and healthy controls (Fig. 1B).

Furthermore, we extended our analysis on a second gene named *GJA-1* (Gap junction alpha-1 protein) which encodes protein known as *Connexin43* (*Cx43*) and has been previously shown as down regulated in expression specifically in major depressive disorder [18–21]. Reduced levels of *Cx43* and *Cx30* mRNA in the dorsal lateral prefrontal cortex (DLPFC) of subjects diagnosed with psychiatric disorder and committed suicide are described previously [22]. Similarly, low levels of *Cx43* mRNA were detected in the locus coeruleus (LC) in depression subjects [23]. At this chromosome 6

locus, we determined methylation status at seven CpG sites of *GJA-1* genomic region as previously described by Jinn et al., 2010 [24]. Here again, our pyrosequencing analysis did not detect any significant difference among patients and healthy individuals. The DNA methylation levels were found to be very low (1–3%) for these selective sites (Fig. 1C).

Moreover, it has been argued that women have stronger tendency towards depression than men [25], but in our analysis no difference was observed among male and female subgroups, indicating that gender has no impact on DNA methylation levels for these particular genes in depression phenotype. In conclusion, *DLG4* and *GJA-1* did not show any alteration of DNA methylation in brain tissues isolated from depression patients.

3. Subjects and methods

Genomic DNA from brain tissues of six individuals diagnosed with MDD (4 females, 2 males) were used, aged 76.3 ± 19.5 years (PFC) and 76.8 ± 19.6 years (HIP), and the mean postmortem intervals were 5.6 ± 1.0 h (PFC) and 6.2 ± 1.6 h (HIP). Control tissue specimens had a mean tissue pH of 6.8 ± 0.3 and mean postmortem interval of 6.1 ± 0.7 h and were obtained from six healthy donors (4 females, 2 males) aged 78.8 ± 14.2 years. DNA was isolated using standard protocols. Detail description of patient samples has been given in Kaut et al., 2015 [26]. Bisulfite conversion for methylation analysis was performed using the EZ DNA Methylation-Gold Kit (Zymo Research, Hiss Diagnostics, Freiburg, Germany) according to the manufacturer's instructions. Bisulfite-treated DNA samples were used for PCR with the PSD-95 and GJA-1 gene specific primers using HotStartTaq (Qiagen). Detail of primer sequences are following: *DLG4* (CpG1-3) forward: 5'-TGGTAGGGAATATGTGTGTTT-3'; *DLG4* (CpG1-3) reverse biotinylated: 5'-ACCTAAACTCTCCTTAAAACTCT-3'; *DLG4* (CpG1-3) pyrosequencing: 5'-AATATAATTTTTTTTGTAGTTTGTG-3'; *DLG4* (CpG4-6) forward: 5'-AGTTT TTTTTGGGGAGGAAAGAG-3'; *DLG4* (CpG4-6) reverse biotinylated: 5'-ACCCCTAAAATAATCCCTTATAC-3'; *DLG4* (CpG4-6) pyrosequencing: 5'-TTAGGTTTTTTTAAATAAGTTTT-3' and primers for GJA-1 are forward: 5'-GTGGAAGTATTTGTATTAGTGAATG-3'; GJA-1 reverse biotinylated: 5'-CCCAAACCCRAACTAATTC-3'; GJA-1 pyrosequencing: 5'-TGTTGAAAAGTAAATAAAAATG-3' respectively. Pyrosequencing was carried out on a PyroMark Q24 instrument (Qiagen) according to the manufacturer's instruction and methylation analysis was performed by taking mean of all analyzed CpG sites. In all statistical calculation the significance was set at $p < 0.05$. All subjects gave written consent and the study was approved by the local ethical committee (51/100).

Ethical approval

The Ethics Committee of the Medical Faculty of the University of Bonn approved the study (No. 51/00, 6th July 2000).

Conflicts of interests

The authors declare no conflict of interests.

Acknowledgments

We thank all the patients who participated in this study. We also thank Sabine Proske-Schmitz for technical support. The study was supported by the German Federal Ministry of Education and Research (BMBF/ANR) through the EpiPD (Epigenomics of Parkinson's disease) project, under the auspices of the bilateral Epigenomics of Common and Age-related Diseases Programme (grant # 01KU1403B; UW).

References

- [1] Rudenko A, Tsai LH. Epigenetic regulation in memory and cognitive disorders. *Neuroscience* 2014;264:51–63.

- [2] Fass DM, Schroeder FA, Perlis RH, Haggarty SJ. Epigenetic mechanisms in mood disorders: targeting neuroplasticity. *Neuroscience* 2014;264:112–30.
- [3] Fagiolini M, Jensen CL, Champagne FA. Epigenetic influences on brain development and plasticity. *Curr Opin Neurobiol* 2009;19:207–12.
- [4] McGowan PO, Sasaki A, D'alessio AC, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. *Nat Neurosci* 2009;12:342–8.
- [5] Murgatroyd C, Patchev AV, Wu Y, et al. Dynamic DNA methylation programs persistent adverse effects of early-life stress. *Nat Neurosci* 2009;12:1559–66.
- [6] Weaver ICG, Cervoni N, Champagne FA, et al. Epigenetic programming by maternal behavior. *Nature Neurosci* 2004;7:847–54.
- [7] Schroeder FA, Lin CL, Crusio WE, Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. *Biol Psychiatry* 2007;62:55–64.
- [8] Davies MN, Krause L, Bell JT, et al. Hypermethylation in the ZBTB20 gene is associated with major depressive disorder. *Genome Biol* 2014;15:R56.
- [9] Oh G, Wang SC, Pal M, et al. DNA modification study of major depressive disorder: beyond locus-by-locus comparisons. *Biol Psychiatry* 2015;77(246–55):63.
- [10] Kang HJ, Kim JM, Stewart R, et al. Association of SLC6A4 methylation with early adversity, characteristics and outcomes in depression. *Prog Neuropsychopharmacol Biol Psychiatry* 2013;44:23–8.
- [11] D'Addario C, Dell'Osso B, Galimberti D, et al. Epigenetic modulation of BDNF gene in patients with major depressive disorder. *Biol Psychiatry* 2013;73:e6–7.
- [12] Zill P, Baghai TC, Schüle C, et al. DNA methylation analysis of the angiotensin converting enzyme (ACE) gene in major depression. *PLoS One* 2012;7:e40479.
- [13] Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. *Prog Neuro-Psychopharmacol Biol Psychiatry* 2009;33(1):70–5.
- [14] Kristiansen LV, Meador-Woodruff JH. Abnormal striatal expression of transcripts encoding NMDA interacting PSD proteins in schizophrenia, bipolar disorder and major depression. *Schizophr Res* 2005;78:87–93.
- [15] Toro C, Deakin JF. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. *Schizophr Res* 2005;80:323–30.
- [16] Feyissa AM, Chandran A, Stockmeier CA, Karolewicz B. Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. *Prog. Neuropsychopharmacol. Biol. Psychiatry* 2009;33:70–5.
- [17] Karolewicz B, Szebeni K, Gilmore T, et al. Elevated levels of NR2A and PSD-95 in the lateral amygdala in depression. *Int J Neuropsychopharmacol* 2008.
- [18] Medina A, Watson SJ, Bunney Jr W, et al. Evidence for alterations of the glial syncytial function in major depressive disorder. *J. Psychiatr. Res* 2015;72:15–21.
- [19] Miguel-Hidalgo JJ, Wilson BA, Hussain S, et al. Reduced connexin 43 immunolabeling in the orbitofrontal cortex in alcohol dependence and depression. *J Psychiatr Res* 2014;55:101–9.
- [20] Sun JD, Liu Y, Yuan YH, et al. Gap junction dysfunction in the prefrontal cortex induces depressive-like behaviors in rats. *Neuropsychopharmacology* 2012;37:1305–20.
- [21] Quesseveur G, Portal B, Basile J-A, et al. Attenuated levels of hippocampal connexin 43 and its phosphorylation correlate with antidepressant- and anxiolytic-like activities in mice. *Front Cell Neurosci* 2015;9:490.
- [22] Ernst C, Nagy C, Kim S, et al. Dysfunction of astrocyte connexins 30 and 43 in dorsal lateral prefrontal cortex of suicide completers. *Biol Psychiatry* 2011;70:312–9.
- [23] Bernard R, Kerman IA, Thompson RC, et al. Altered expression of glutamate signaling, growth factor, and glia genes in the locus coeruleus of patients with major depression. *Mol Psychiatry* 2011;16:634–46.
- [24] Jinn Y, Inase N. Connexin 43, E-cadherin, β -catenin and ZO-1 expression, and aberrant methylation of the connexin43 gene in NSCLC. *Anticancer Res* 2010;30:2271–8.
- [25] Wang K, Lu H, Cheung EFC, et al. "Female preponderance" of depression in non-clinical populations: a meta-analytic study. *Front Psychol* 2016;7:1398.
- [26] Kaut O, Schmitt I, Hofmann A, et al. Aberrant NMDA receptor DNA methylation detected by epigenome-wide analysis of hippocampus and prefrontal cortex in major depression. *Eur Arch Psychiatry Clin Neurosci* 2015;265(4):331–41.